BACKGROUND: Heightened immune activation among human immunodeficiency virus (HIV)-infected persons may contribute to atherosclerosis. We assessed associations of serologic markers of monocyte activation, soluble CD163 (sCD163) and soluble CD14 (sCD14), and monocyte chemoattractant protein 1 (CCL2) with subclinical atherosclerosis among men with and those without HIV infection in the Multicenter AIDS Cohort Study. METHODS: We performed noncontrast computed tomography on 906 men (566 HIV-infected men and 340 HIV-uninfected men), 709 of whom also underwent coronary computed tomographic angiography. Associations between each biomarker and the prevalence of coronary plaque, the prevalence of stenosis of ≥50%, and the extent of plaque were assessed by logistic and linear regression, adjusting for age, race, HIV serostatus, and cardiovascular risk factors. RESULTS: Levels of all biomarkers were higher among HIV-infected men, of whom 81% had undetectable HIV RNA, and were associated with lower CD4(+) T-cell counts. In the entire population and among HIV-infected men, higher biomarker levels were associated with a greater prevalence of coronary artery stenosis of ≥50%. Higher sCD163 levels were also associated with greater prevalences of coronary artery calcium, mixed plaque, and calcified plaque; higher CCL2 levels were associated with a greater extent of noncalcified plaque. CONCLUSIONS: sCD163, sCD14, and CCL2 levels were elevated in treated HIV-infected men and associated with atherosclerosis. Monocyte activation may increase the risk for cardiovascular disease in individuals with HIV infection.
BACKGROUND: Heightened immune activation among human immunodeficiency virus (HIV)-infectedpersons may contribute to atherosclerosis. We assessed associations of serologic markers of monocyte activation, soluble CD163 (sCD163) and soluble CD14 (sCD14), and monocyte chemoattractant protein 1 (CCL2) with subclinical atherosclerosis among men with and those without HIV infection in the Multicenter AIDS Cohort Study. METHODS: We performed noncontrast computed tomography on 906 men (566 HIV-infectedmen and 340 HIV-uninfectedmen), 709 of whom also underwent coronary computed tomographic angiography. Associations between each biomarker and the prevalence of coronary plaque, the prevalence of stenosis of ≥50%, and the extent of plaque were assessed by logistic and linear regression, adjusting for age, race, HIV serostatus, and cardiovascular risk factors. RESULTS: Levels of all biomarkers were higher among HIV-infectedmen, of whom 81% had undetectable HIV RNA, and were associated with lower CD4(+) T-cell counts. In the entire population and among HIV-infectedmen, higher biomarker levels were associated with a greater prevalence of coronary artery stenosis of ≥50%. Higher sCD163 levels were also associated with greater prevalences of coronary artery calcium, mixed plaque, and calcified plaque; higher CCL2 levels were associated with a greater extent of noncalcified plaque. CONCLUSIONS: sCD163, sCD14, and CCL2 levels were elevated in treated HIV-infectedmen and associated with atherosclerosis. Monocyte activation may increase the risk for cardiovascular disease in individuals with HIV infection.
Authors: W G Austen; J E Edwards; R L Frye; G G Gensini; V L Gott; L S Griffith; D C McGoon; M L Murphy; B B Roe Journal: Circulation Date: 1975-04 Impact factor: 29.690
Authors: David H McDermott; Qiong Yang; Sekar Kathiresan; L Adrienne Cupples; Joseph M Massaro; John F Keaney; Martin G Larson; Ramachandran S Vasan; Joel N Hirschhorn; Christopher J O'Donnell; Philip M Murphy; Emelia J Benjamin Journal: Circulation Date: 2005-08-23 Impact factor: 29.690
Authors: Lehn K Weaver; Katharine A Hintz-Goldstein; Patricia A Pioli; Kathleen Wardwell; Nilofer Qureshi; Stefanie N Vogel; Paul M Guyre Journal: J Leukoc Biol Date: 2006-07 Impact factor: 4.962
Authors: Jacob M van Werkhoven; Joanne D Schuijf; Oliver Gaemperli; J Wouter Jukema; Eric Boersma; William Wijns; Paul Stolzmann; Hatem Alkadhi; Ines Valenta; Marcel P M Stokkel; Lucia J Kroft; Albert de Roos; Gabija Pundziute; Arthur Scholte; Ernst E van der Wall; Philipp A Kaufmann; Jeroen J Bax Journal: J Am Coll Cardiol Date: 2009-02-17 Impact factor: 24.094
Authors: Jeroen P H van Wijk; Eelco J P de Koning; Manuel Castro Cabezas; Jorge Joven; Jos op't Roodt; Ton J Rabelink; Andy M Hoepelman Journal: J Am Coll Cardiol Date: 2006-02-23 Impact factor: 24.094
Authors: Joshua A Walker; Andrew D Miller; Tricia H Burdo; Michael S McGrath; Kenneth C Williams Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Martin Tibuakuu; Di Zhao; Ankita Saxena; Todd T Brown; Lisa P Jacobson; Frank J Palella; Mallory D Witt; Susan L Koletar; Joseph B Margolick; Eliseo Guallar; Sai Krishna C Korada; Matthew J Budoff; Wendy S Post; Erin D Michos Journal: J Cardiovasc Comput Tomogr Date: 2018-01-31
Authors: Jose R Castillo-Mancilla; Todd T Brown; Kristine M Erlandson; Frank J Palella; Edward M Gardner; Bernard J C Macatangay; Elizabeth C Breen; Lisa P Jacobson; Peter L Anderson; Nikolas I Wada Journal: Clin Infect Dis Date: 2016-09-22 Impact factor: 9.079
Authors: Melissa E Schechter; Bruno B Andrade; Tianyu He; George Haret Richter; Kevin W Tosh; Benjamin B Policicchio; Amrit Singh; Kevin D Raehtz; Virginia Sheikh; Dongying Ma; Egidio Brocca-Cofano; Cristian Apetrei; Russel Tracy; Ruy M Ribeiro; Alan Sher; Ivo M B Francischetti; Ivona Pandrea; Irini Sereti Journal: Sci Transl Med Date: 2017-08-30 Impact factor: 17.956